151. PEGylation but Not Fc-Fusion Improves in Vivo Residence Time of a Thermostable Mutant of Bacterial Cocaine Esterase.
- Author
-
Huang H, Fang L, Xue L, Zhang T, Kim K, Hou S, Zheng F, and Zhan CG
- Subjects
- Animals, Bacterial Proteins, Carboxylic Ester Hydrolases genetics, Carboxylic Ester Hydrolases pharmacokinetics, Drug Design, Escherichia coli genetics, Half-Life, Immunoglobulin Fc Fragments chemistry, Immunoglobulin Fc Fragments pharmacology, Immunoglobulin G immunology, Mutant Proteins chemistry, Mutant Proteins pharmacokinetics, Polyethylene Glycols pharmacology, Proteolysis drug effects, Rats, Carboxylic Ester Hydrolases chemistry, Enzyme Stability drug effects, Polyethylene Glycols chemistry
- Abstract
It is very popular to fuse a protein drug or drug candidate to the Fc domain of immunoglobulin G (IgG) in order to prolong the in vivo half-life. In this study, we have designed, prepared, and tested an Fc-fused thermostable cocaine esterase (CocE) mutant (known as E196-301, with the T172R/G173Q/L196C/I301C substitutions on CocE) expressed in E. coli . As expected, Fc-fusion does not affect the in vitro enzyme activity and thermal stability of the enzyme and that Fc-E196-301 can favorably bind FcRn with K
d = 386 ± 35 nM. However, Fc-fusion does not prolong the in vivo half-life of E196-301 at all; Fc-E196-301 and E196-301 have essentially the same PK profile ( t1/2 = 0.4 ± 0.1 h) in rats. This is the first time demonstrating that Fc-fusion does not prolong in vivo half-life of a protein. This finding is consistent with the mechanistic understanding that E196-301 and Fc-E196-301 are all degraded primarily through rapid proteolysis in the body. The Fc fusion cannot protect E196-301 from the proteolysis in the body. Nevertheless, it has been demonstrated that PEGylation can effectively protect E196-301, as the PEGylated E196-301, i.e., PEG-E196-301, has a significantly prolonged in vivo half-life. It has also been demonstrated that both E196-301 and PEG-E196-301 have dose-dependent in vivo half-lives (e.g., 19.9 ± 6.4 h for the elimination t1/2 of 30 mg/kg PEG-E196-301), as the endogenous proteolytic enzymes responsible for proteolysis of E196-301 (PEGylated or not) are nearly saturated by the high plasma concentration produced by a high dose of E196-301 or PEG-E196-301.- Published
- 2019
- Full Text
- View/download PDF